Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: long-term follow-up of the AML17 trial

Nigel Russell, Alan Burnett, Robert Hills, Sophie Betteridge, Mike Dennis, Jelena Jovanovic, Richard Dillon and David Grimwade on behalf of the NCRI AML Working Group
PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.